Masimo Corporation (NASDAQ:MASI) Shares Acquired by Calamos Advisors LLC

Calamos Advisors LLC boosted its holdings in shares of Masimo Corporation (NASDAQ:MASI - Free Report) by 44.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,449 shares of the medical equipment provider's stock after acquiring an additional 7,169 shares during the quarter. Calamos Advisors LLC's holdings in Masimo were worth $3,907,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of MASI. Jones Financial Companies Lllp purchased a new position in Masimo during the 4th quarter valued at $27,000. Farther Finance Advisors LLC boosted its holdings in Masimo by 128.9% during the 1st quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 116 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 64 shares during the period. Smartleaf Asset Management LLC boosted its holdings in Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 60 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new position in Masimo during the 4th quarter valued at $46,000. Hedge funds and other institutional investors own 85.96% of the company's stock.

Analyst Ratings Changes

MASI has been the subject of a number of recent analyst reports. Raymond James Financial dropped their price objective on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Piper Sandler reiterated an "overweight" rating and issued a $200.00 target price (down from $215.00) on shares of Masimo in a report on Wednesday, May 7th. Wall Street Zen lowered Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. BTIG Research set a $193.00 price target on Masimo and gave the company a "buy" rating in a research note on Wednesday, May 7th. Finally, Needham & Company LLC restated a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $191.60.

Masimo Stock Down 1.2%

Shares of MASI traded down $2.08 during trading hours on Monday, hitting $165.50. The company had a trading volume of 225,907 shares, compared to its average volume of 637,683. The company has a market capitalization of $8.97 billion, a PE ratio of -18.12 and a beta of 1.19. The company has a current ratio of 2.17, a quick ratio of 1.62 and a debt-to-equity ratio of 0.67. Masimo Corporation has a one year low of $101.61 and a one year high of $194.88. The company's fifty day moving average price is $161.89 and its two-hundred day moving average price is $166.46.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 EPS for the quarter, topping the consensus estimate of $1.24 by $0.12. The firm had revenue of $372.00 million during the quarter, compared to analyst estimates of $367.79 million. Masimo had a positive return on equity of 22.56% and a negative net margin of 25.06%. The business's revenue for the quarter was down 24.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.77 EPS. As a group, equities analysts forecast that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Insider Activity at Masimo

In other Masimo news, COO Bilal Muhsin sold 10,000 shares of the firm's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $163.28, for a total value of $1,632,800.00. Following the completion of the sale, the chief operating officer owned 24,172 shares of the company's stock, valued at approximately $3,946,804.16. This trade represents a 29.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 16.90% of the company's stock.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.